Patients who benefit most from receiving a Barricaid® are those at greater risk of recurrent herniation and/or disc collapse. These patients are identified as having a tall disc1 height in combination with a large anular defect.

Conversely patients with small or slit-type defects have as low as 1% risk of recurrence, and therefore do not benefit from anular closure treatment.

≥5mm posterior disc height as measured on MRI. Internal data on file at Intrinsic Therapeutics.


  • Skeletally mature patients with disc herniations (primary or recurrent) between L4 and S1 with radiographic confirmation of neural compression using MRI.
  • Minimum posterior disc height of 5mm at the index level.
  • Intra-operative confirmation of an anular defect that is between 4mm – 6mm in height and between 6mm – 12mm in width.


  • Do not implant the Barricaid device in case of spondylolisthesis and/or instability requiring stabilization.
  • Do not use the Barricaid device in anular defects wider than 12mm or taller than 6mm.
  • Do not implant the Barricaid device if subject has clinically compromised vertebral bodies in the lumbosacral region due to any traumatic, neoplastic, metabolic, or infectious pathology.
  • Do not implant the Barricaid device in case of osteoporosis.
  • Do not implant the Barricaid device in case of extraforaminal herniations and any defect you cannot completely visualize.
Refer to the Barricaid Instructions for Use (220119-EU) for a complete list of contraindications and warnings.